Land: Europäische Union
Sprache: Englisch
Quelle: EMA (European Medicines Agency)
ombitasvir / paritaprevir / ritonavir
AbbVie Ltd
ombitasvir / paritaprevir / ritonavir
Antivirals for systemic use
Hepatitis C, Chronic
Viekirax is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.
Authorised
2015-01-15
69 B. PACKAGE LEAFLET 70 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT VIEKIRAX 12.5 MG/75 MG/50 MG FILM-COATED TABLETS ombitasvir/paritaprevir/ritonavir This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Viekirax is and what it is used for 2. What you need to know before you take Viekirax 3. How to take Viekirax 4. Possible side effects 5. How to store Viekirax 6. Contents of the pack and other information 1. WHAT VIEKIRAX IS AND WHAT IT IS USED FOR Viekirax is an antiviral medicine used to treat adults with chronic (long-term) hepatitis C (an infectious disease that affects the liver, caused by the hepatitis C virus). It contains the active substances ombitasvir, paritaprevir and ritonavir. The combined action of the three active substances stops the hepatitis C virus from multiplying and infecting new cells, thus clearing the virus from your blood over a period of time. Ombitasvir and paritaprevir block two proteins essential for the virus to multiply. Ritonavir acts as a ‘booster’ to prolong the action of paritaprevir in the body. Viekirax tablets are taken with other antiviral medicines _ _ such as dasabuvir and ribavirin. Your doctor will talk with you about which of these medicines to take with Viekirax. It is very important that you also read the package l Lesen Sie das vollständige Dokument
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions . 1. NAME OF THE MEDICINAL PRODUCT Viekirax 12.5 mg/75 mg/50 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 12.5 mg of ombitasvir, 75 mg of paritaprevir and 50 mg of ritonavir. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet). Pink, oblong, biconvex, film-coated tablets of dimensions 18.8 mm x 10.0 mm, debossed on one side with ‘AV1’. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Viekirax is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults (see sections 4.2, 4.4, and 5.1). For hepatitis C virus (HCV) genotype specific activity, see sections 4.4 and 5.1. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment with Viekirax should be initiated and monitored by a physician experienced in the management of chronic hepatitis C. Posology The recommended oral dose of Viekirax is two 12.5 mg / 75 mg / 50 mg tablets once daily with food. Viekirax should be used in combination with other medicinal products for the treatment of HCV (see Table 1). 3 TABLE 1. RECOMMENDED CO-ADMINISTERED MEDICINAL PRODUCT(S) AND TREATMENT DURATION FOR VIEKIRAX BY PATIENT POPULATION PATIENT POPULATION TREATMENT* DURATION GENOTYPE 1B, WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS Viekirax + dasabuvir 12 weeks 8 weeks may be considered in previously untreated genotype 1b- infected patients with minimal to moderate fibrosis** (see section 5.1, GARNET study) GENOTYPE 1A, WITHOUT CIRRHOSIS Viekirax + dasabuvir + ribavirin* 12 weeks GENOTYPE 1A, WITH COMPENSATED CIRRHOSIS Viekirax + dasabuvir + ribavirin* 24 weeks (see section 5.1.) GENOTYPE 4, WITHOUT CIRRHOSIS OR WITH COMPENSATED Lesen Sie das vollständige Dokument